|
1
|
Thayer SP, di Magliano MP, Heiser PW,
Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del
Castillo C, Yajnik V, et al: Hedgehog is an early and late mediator
of pancreatic cancer tumorigenesis. Nature. 425:851–856. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosetti C, Bertuccio P, Negri E, La
Vecchia C, Zeegers MP and Boffetta P: Pancreatic cancer: Overview
of descriptive epidemiology. Mol Carcinog. 51:3–13. 2012.
View Article : Google Scholar
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kleger A, Perkhofer L and Seufferlein T:
Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol.
25:1260–1270. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haberland J, Bertz J, Wolf U, Ziese T and
Kurth BM: German cancer statistics 2004. BMC Cancer. 10:522010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vaccaro V, Sperduti I and Milella M:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 365:768–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D and Wolff RA;
National Cancer Institute of Canada Clinical Trials Group:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang SP and Saif MW: Optimal second line
treatment options for gemcitabine refractory advanced pancreatic
cancer patients. Can we establish standard of care with available
data? JOP. 9:83–90. 2008.PubMed/NCBI
|
|
11
|
Bergmann U, Funatomi H, Yokoyama M, Beger
HG and Korc M: Insulin-like growth factor I overexpression in human
pancreatic cancer: Evidence for autocrine and paracrine roles.
Cancer Res. 55:2007–2011. 1995.PubMed/NCBI
|
|
12
|
Rieder S, Michalski CW, Friess H and
Kleeff J: Insulin-like growth factor signaling as a therapeutic
target in pancreatic cancer. Anticancer Agents Med Chem.
11:427–433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seo Y, Baba H, Fukuda T, Takashima M and
Sugimachi K: High expression of vascular endothelial growth factor
is associated with liver metastasis and a poor prognosis for
patients with ductal pancreatic adenocarcinoma. Cancer.
88:2239–2245. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kindler HL, Niedzwiecki D, Hollis D,
Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF,
O'Reilly E, Wozniak TF, et al: Gemcitabine plus bevacizumab
compared with gemcitabine plus placebo in patients with advanced
pancreatic cancer: Phase III trial of the Cancer and Leukemia Group
B (CALGB 80303). J Clin Oncol. 28:3617–3622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hannenhalli S and Kaestner KH: The
evolution of Fox genes and their role in development and disease.
Nat Rev Genet. 10:233–240. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carter ME and Brunet A: FOXO transcription
factors. Curr Biol. 17:R113–R114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paik JH, Kollipara R, Chu G, Ji H, Xiao Y,
Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, et al: FoxOs are
lineage-restricted redundant tumor suppressors and regulate
endothelial cell homeostasis. Cell. 128:309–323. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tothova Z, Kollipara R, Huntly BJ, Lee BH,
Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams
IR, Sears C, et al: FoxOs are critical mediators of hematopoietic
stem cell resistance to physiologic oxidative stress. Cell.
128:325–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Z, Ahmad A, Li Y, Banerjee S, Kong D
and Sarkar FH: Forkhead box M1 transcription factor: A novel target
for cancer therapy. Cancer Treat Rev. 36:151–156. 2010. View Article : Google Scholar :
|
|
20
|
Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF,
Chen LZ, Xue L, Li Z and Li W: Overexpression of FOXM1 is
associated with poor prognosis and clinicopathologic stage of
pancreatic ductal adenocarcinoma. Pancreas. 41:629–635. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Banerjee S, Kong D, Li Y and
Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic
cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang G, He P, Gaedcke J, Ghadimi BM, Ried
T, Yfantis HG, Lee DH, Hanna N, Alexander HR and Hussain SP: FOXL1,
a novel candidate tumor suppressor, inhibits tumor aggressiveness
and predicts outcome in human pancreatic cancer. Cancer Res.
73:5416–5425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arnold HK and Sears RC: A tumor suppressor
role for PP2A-B56alpha through negative regulation of c-Myc and
other key oncoproteins. Cancer Metastasis Rev. 27:147–158. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Westermarck J and Hahn WC: Multiple
pathways regulated by the tumor suppressor PP2A in transformation.
Trends Mol Med. 14:152–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eichhorn PJ, Creyghton MP and Bernards R:
Protein phosphatase 2A regulatory subunits and cancer. Biochim
Biophys Acta. 1795:1–15. 2009.
|
|
26
|
Farrell AS, Pelz C, Wang X, Daniel CJ,
Wang Z, Su Y, Janghorban M, Zhang X, Morgan C, Impey S, et al: Pin1
regulates the dynamics of c-Myc DNA binding to facilitate target
gene regulation and oncogenesis. Mol Cell Biol. 33:2930–2949. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sears RC: The life cycle of c-Myc: From
synthesis to degradation. Cell Cycle. 3:1133–1137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Welcker M, Orian A, Grim JE, Eisenman RN
and Clurman BE: A nucleolar isoform of the Fb 7 ubiquitin ligase
regulates c-Myc and cell size. Curr Biol. 14:1852–1857. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Côme C, Laine A, Chanrion M, Edgren H,
Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al:
CIP2A is associated with human breast cancer aggressivity. Clin
Cancer Res. 15:5092–5100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang L, Gu F, Ma N, Zhang L, Bian JM and
Cao HY: CIP2A expression is associated with altered expression of
epithelial-mesenchymal transition markers and predictive of poor
prognosis in pancreatic ductal adenocarcinoma. Tumour Biol.
34:2309–2313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Szymczak AL, Workman CJ, Wang Y, Vignali
KM, Dilioglou S, Vanin EF and Vignali DA: Correction of multi-gene
deficiency in vivo using a single 'self-cleaving' 2A peptide-based
retroviral vector. Nat Biotechnol. 22:589–594. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ashkenazi A: Targeting death and decoy
receptors of the tumour-necrosis factor superfamily. Nat Rev
Cancer. 2:420–430. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
He C, Jiang H, Geng S, Sheng H, Shen X,
Zhang X, Zhu S, Chen X, Yang C and Gao H: Expression of c-Myc and
Fas correlates with perineural invasion of pancreatic cancer. Int J
Clin Exp Pathol. 5:339–346. 2012.PubMed/NCBI
|
|
35
|
Janghorban M, Farrell AS, Allen-Petersen
BL, Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ and Sears
RC: Targeting c-MYC by antagonizing PP2A inhibitors in breast
cancer. Proc Natl Acad Sci USA. 111:9157–9162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sarkar FH, Banerjee S and Li Y: Pancreatic
cancer: Pathogenesis, prevention and treatment. Toxicol Appl
Pharmacol. 224:326–336. 2007. View Article : Google Scholar
|
|
37
|
Berman DM, Karhadkar SS, Maitra A, Montes
De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman
JR, Watkins DN, et al: Widespread requirement for Hedgehog ligand
stimulation in growth of digestive tract tumours. Nature.
425:846–851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liptay S, Weber CK, Ludwig L, Wagner M,
Adler G and Schmid RM: Mitogenic and antiapoptotic role of
constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J
Cancer. 105:735–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nakashima H, Nakamura M, Yamaguchi H,
Yamanaka N, Akiyoshi T, Koga K, Yamaguchi K, Tsuneyoshi M, Tanaka M
and Katano M: Nuclear factor-kappaB contributes to hedgehog
signaling pathway activation through sonic hedgehog induction in
pancreatic cancer. Cancer Res. 66:7041–7049. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Farrell AS, Allen-Petersen B, Daniel CJ,
Wang X, Wang Z, Rodriguez S, Impey S, Oddo J, Vitek MP, Lopez C, et
al: Targeting inhibitors of the tumor suppressor PP2A for the
treatment of pancreatic cancer. Mol Cancer Res. 12:924–939. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ryan MD, King AM and Thomas GP: Cleavage
of foot-and-mouth disease virus polyprotein is mediated by residues
located within a 19 amino acid sequence. J Gen Virol. 72:2727–2732.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sharma P, Yan F, Doronina VA,
Escuin-Ordinas H, Ryan MD and Brown JD: 2A peptides provide
distinct solutions to driving stop-carry on translational recoding.
Nucleic Acids Res. 40:3143–3151. 2012. View Article : Google Scholar :
|
|
44
|
Szymczak-Workman AL, Vignali KM and
Vignali DA: Design and construction of 2A peptide-linked
multicistronic vectors. Cold Spring Harb Protoc. 2012:199–204.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pan G, O'Rourke K, Chinnaiyan AM, Gentz R,
Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand
TRAIL. Science. 276:111–113. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Walczak H, Degli-Esposti MA, Johnson RS,
Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA,
Smith CA, et al: TRAIL-R2: A novel apoptosis-mediating receptor for
TRAIL. EMBO J. 16:5386–5397. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sheridan JP, Marsters SA, Pitti RM, Gurney
A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood
WI, et al: Control of TRAIL-induced apoptosis by a family of
signaling and decoy receptors. Science. 277:818–821. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Newsom-Davis T, Prieske S and Walczak H:
Is TRAIL the holy grail of cancer therapy? Apoptosis. 14:607–623.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mahalingam D, Szegezdi E, Keane M, de Jong
S and Samali A: TRAIL receptor signalling and modulation: Are we on
the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schild C, Wirth M, Reichert M, Schmid RM,
Saur D and Schneider G: PI3K signaling maintains c-myc expression
to regulate transcription of E2F1 in pancreatic cancer cells. Mol
Carcinog. 48:1149–1158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Escamilla-Powers JR and Sears RC: A
conserved pathway that controls c-Myc protein stability through
opposing phosphorylation events occurs in yeast. J Biol Chem.
282:5432–5442. 2007. View Article : Google Scholar
|
|
53
|
Yeh E, Cunningham M, Arnold H, Chasse D,
Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida
T, et al: A signalling pathway controlling c-Myc degradation that
impacts oncogenic transformation of human cells. Nat Cell Biol.
6:308–318. 2004. View Article : Google Scholar : PubMed/NCBI
|
